Compare · AIMT vs EYEG
AIMT vs EYEG
Side-by-side comparison of Aimmune Therapeutics, Inc. (AIMT) and Eyegate Pharmaceuticals, Inc. (EYEG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMT and EYEG operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- EYEG has more recent analyst coverage (1 ratings vs 0 for AIMT).
- Company
- Aimmune Therapeutics, Inc.
- Eyegate Pharmaceuticals, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 1
Eyegate Pharmaceuticals, Inc.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Latest AIMT
- SEC Form SC 13G/A filed
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
- Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
- ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm
- Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
- Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Latest EYEG
- AllianceBernstein Launches Five New Active ETFs
- SEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.
- SEC Form 4 filed by Daniels Eric Joseph
- SEC Form 3 filed by new insider Daniels Eric Joseph
- Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy
- SEC Form D filed by Eyegate Pharmaceuticals, Inc.
- SEC Form 4: From Stephen covered exercise/tax liability with 250 shares, decreasing direct ownership by 0.36% to 68,292 units
- SEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,136 units
- SEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,059 units